Literature DB >> 22642745

SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma.

Shih-Chuan Hsiao1, Inmaculada Ribera Cortada, Luis Colomo, Hongtao Ye, Hongxiang Liu, Szu-Yin Kuo, Shu-Hui Lin, Sheng-Tsung Chang, Ted U Kuo, Elias Campo, Shih-Sung Chuang.   

Abstract

AIMS: To characterize the frequency and clinicopathological features of cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) and the usefulness of SOX11 in the differential diagnosis from mantle cell lymphoma (MCL). METHODS AND
RESULTS: We retrospectively stained 206 consecutive DLBCLs for cyclin D1, and identified three (1.5%) positive cases, comprising two in the elderly with necrosis, and a third with a starry-sky pattern. All three cases shared the same non-germinal centre B-cell (non-GCB) phenotype [CD5-/CD10-/bcl-6+/MUM1+/SOX11-], Epstein-Barr virus (EBV) negativity, and absence of CCND1 aberrations by fluorescence in-situ hybridization. The third case showed both BCL6 and MYC rearrangements: a double-hit lymphoma. In the same period there were 22 MCLs, all expressing cyclin D1, with 89% cases expressing SOX11, a frequency that is statistically different from cyclin D1-positive DLBCL. Notably, we identified a pleomorphic MCL initially misdiagnosed as DLBCL. A separate cohort of 98 DLBCL cases was negative for SOX11, with only one case expressing cyclin D1 with a GCB phenotype (CD10+/bcl-6+/MUM1-). The two patients with tumour necrosis rapidly died of disease. The other two were in complete remission after immunochemotherapy.
CONCLUSION: Cyclin D1-positive DLBCLs are rare, and they are negative for SOX11 or CCND1 aberration. SOX11 is useful in differentiating cyclin D1-positive DLBCL from MCL.
© 2012 Blackwell Publishing Ltd.

Entities:  

Keywords:  CCND1; cyclin D1; diffuse large B-cell lymphoma; double-hit lymphoma; mantle cell lymphoma

Mesh:

Substances:

Year:  2012        PMID: 22642745     DOI: 10.1111/j.1365-2559.2012.04260.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Authors:  David Martín-Garcia; Alba Navarro; Rafael Valdés-Mas; Guillem Clot; Jesús Gutiérrez-Abril; Miriam Prieto; Inmaculada Ribera-Cortada; Renata Woroniecka; Grzegorz Rymkiewicz; Susanne Bens; Laurence de Leval; Andreas Rosenwald; Judith A Ferry; Eric D Hsi; Kai Fu; Jan Delabie; Dennis Weisenburger; Daphne de Jong; Fina Climent; Sheila J O'Connor; Steven H Swerdlow; David Torrents; Sergi Beltran; Blanca Espinet; Blanca González-Farré; Luis Veloza; Dolors Costa; Estella Matutes; Reiner Siebert; German Ott; Leticia Quintanilla-Martinez; Elaine S Jaffe; Carlos López-Otín; Itziar Salaverria; Xose S Puente; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2018-12-11       Impact factor: 22.113

2.  Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.

Authors:  Xiaoyang Xu; Xiaojing Chang; Zhenhua Li; Jiang Wang; Peng Deng; Xinjiang Zhu; Jian Liu; Chundong Zhang; Shuchen Chen; Dongqiu Dai
Journal:  Cell Oncol (Dordr)       Date:  2015-03-24       Impact factor: 6.730

Review 3.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

4.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

Authors:  Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

Review 5.  Aggressive B-cell lymphomas: how many categories do we need?

Authors:  Jonathan W Said
Journal:  Mod Pathol       Date:  2012-11-16       Impact factor: 7.842

6.  Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma.

Authors:  Carla Fuster; David Martín-Garcia; Olga Balagué; Alba Navarro; Ferran Nadeu; Dolors Costa; Miriam Prieto; Itziar Salaverria; Blanca Espinet; Alfredo Rivas-Delgado; Maria José Terol; Eva Giné; Pilar Forcada; Margaret Ashton-Key; Xose S Puente; Steven H Swerdlow; Sílvia Beà; Elias Campo
Journal:  Haematologica       Date:  2019-11-21       Impact factor: 9.941

7.  Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart.

Authors:  Mohamad Zamani-Ahmadmahmudi; Sina Aghasharif; Keyhan Ilbeigi
Journal:  BMC Vet Res       Date:  2017-01-09       Impact factor: 2.741

Review 8.  The pathologic diagnosis of mantle cell lymphoma.

Authors:  Shaoying Li; Jie Xu; M James You
Journal:  Histol Histopathol       Date:  2021-06-11       Impact factor: 2.303

9.  Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.

Authors:  Zhen Jin; Kai Qing; Yuan Ouyang; Zhao Liu; Wenfang Wang; Xiaoyang Li; Zizhen Xu; Junmin Li
Journal:  J Exp Clin Cancer Res       Date:  2016-03-24

10.  Two cases of systemic mantle cell lymphoma involving the skin.

Authors:  Viktoryia Kazlouskaya; Amy Spizuoco; Jacqueline M Junkins-Hopkins
Journal:  Indian Dermatol Online J       Date:  2016 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.